Anzeige
Mehr »
Login
Mittwoch, 13.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Kolumbiens nächster Kupferriese? Warum Investoren dieses 14.000-Meter-Bohrprogramm beobachten!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DDU5 | ISIN: SE0015244884 | Ticker-Symbol: P52
Frankfurt
13.11.24
15:29 Uhr
0,256 Euro
-0,006
-2,29 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
NEWBURY PHARMACEUTICALS AB Chart 1 Jahr
5-Tage-Chart
NEWBURY PHARMACEUTICALS AB 5-Tage-Chart
GlobeNewswire (Europe)
41 Leser
Artikel bewerten:
(0)

Newbury Pharmaceuticals AB: Newbury Pharmaceuticals interim report September 2023 - May 2024

Finanznachrichten News

Quarter 3, March 2024 - May 2024
· Net revenue was 1 386 (5 680) tkr.
· EBITDA was -7 861 (-3 872) tkr.
· Operating cash flow was -10 182 (-8 532) tkr.

Interim period, September 2023 - May 2024
· Net revenue was 15 706 (7 439) tkr.
· EBITDA was -14 742 (-13 864) tkr.
· Operating cash flow was -23 837 (-19 596) tkr.
· Cash position in the end of period was 15 431 (12 927) tkr.
· Licensed products at the end of period were 31 (33).
· Products with distribution rights at the end of the period were 12 (2).
· Products with marketing authorization in the end of the period were 21 (12).
· Products launched in Nordics at end of the period 8 (2).

Significant events during the quarter
· Newbury carried out a directed share issue of approximately 19 mkr at a subscription price on 4 kr per share. After the Share Issue, the number of outstanding shares in Newbury increases by 4 737 500 shares, from 19 521 154 to 24 258 654 shares.

Significant events after the end of the quarter
· Newbury Pharmaceuticals is strengthening its portfolio with Dalbavancin Powder, replacing a previously signed product, Daptomycin, from the same partner. The commercial attractiveness is judged to be better for Dalbavancin and no additional in-licensing fees will be paid.
· Newbury Pharmaceuticals Secures Generic Approval for Liraglutide Pre-Filled Pen in Denmark.
· Initiated commercialisation of various Amarox products in Sweden.

A word from the CEO
A slow quarter due to delayed invoicing of an international sales order, but optimistic future ahead of us.

Sales uptake in Scandinavia and a delayed international sales order
Sales during this quarter were lower than anticipated, but for a good reason. The announced international sales order (8 800 tkr) planned for shipment in May was postponed to June which is the next reporting period.

The direct sales in Scandinavia reached +146% growth over the same period last year attributed to the launch of more products. This growth continues with record sales in June which is the next reporting period. As of today, we have launched 11 products in Scandinavia, and we see the fruits of having a diverse portfolio with more options to win tenders where June will be a strong month.

We have also started sell the first products from the partnership with Amarox Ltd. In June we made the first launches and won the monthly tender for two products. This collaboration is an excellent supplement to our own portfolio. Furthermore, it has financial advantages with limited risk and investments on our side.

Portfolio development
We have recently obtained registration of Liraglutide Newbury which will be launched to compete with Victoza from Novo Nordisk and thereby help diabetic patients access this product which has been faced with supply challenges over the past couple of months. As a result of the supply challenges, many patients have been upgraded to Ozempic. However, we believe that we can offer an alternative to these patients and thereby also reduce the supply risk for patients. We are currently evaluating the expected sales uptake in this volatile treatment segment - e.g. reimbursement in Denmark has been removed recently.

We have also been able to switch Daptomycin to the more interesting product Dalbavancin. We see much more potential for this product, and we are pleased to enrich our portfolio with this specialty product.

We have a good foundation for continued growth and will pursue to broaden the business during the coming months with more launches, more product approvals and potentially new partnerships.

Financial development
Sales was impacted by the delayed order while the operating result is impacted by one-off items hitting this quarter. We have ahead of the Q4 report and based on sound accounting policies made reservations for delayed payment from an international sales order totalling (2 796 tkr) and at the same time made reservation for a product with low shelf life left for sales amounting to 366 tkr.

The cash position was improved with the directed share issue and we expect further payments of outstanding international sales. However, as any company we closely monitor our cash position to be equipped for new investment opportunities as well as safeguarding financials by strict monitoring of account receivables.

Looking ahead
Strong sales in June will help fuel growth in the next quarter and we have some interesting sales opportunities for a couple of products ahead of us - both short-term and long-term opportunities.

The Amarox partnership will continue to fuel new launches in the next months which will help expand the number of launched products.

We work very hard to achieve sales and thereby reach a positive EBITDA during one of the coming quarters, but one challenge is the volatility in tender sales as we rely on only a few products.

We are pleased with our achievements which will secure the continued focus on executing our growth plans by launching additional products and building a stronger company for the future.

The report is publised on Newbury Pharmaceuticals website:
https://www.newburypharma.com/investors/financial-information/

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

This information is information that Newbury Pharmaceuticals is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-07-10 08:00 CEST.

© 2024 GlobeNewswire (Europe)
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.